
|Videos|July 23, 2018
Therapeutic Approach for IDH2-Mutated AML
Therapeutic Approach for IDH2-Mutated AML
Advertisement
Case: A 65-Year-Old Woman withIDH2-Mutated AML
November 2017
- A 65-year-old female was diagnosed with AML, normal cytogenetics;IDH2R140,RUNX1,andDNMT3Amutations
- 7+3 induction chemotherapy was initiated
- Her treatment course was complicated by mucositis and febrile neutropenia
- After resolution of her complications, she received 2 cycles of intermediate-dose cytarabine consolidation
May 2018
- Now, 6 months after her initial diagnosis, she presents with fatigue, aches, and gum bleeding
- Labs: leukocytosis, 20% circulating myeloblasts, ANC 450 cells/mL
- Bone marrow biopsy: hypercellular 80% blast, normal cytogenetics
- NGS: mutations inIDH2,RUNX1,andDNMT3A
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
3
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5
































